1824 related articles for article (PubMed ID: 26384238)
41. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
[TBL] [Abstract][Full Text] [Related]
42. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
[TBL] [Abstract][Full Text] [Related]
43. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
[TBL] [Abstract][Full Text] [Related]
44. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
45. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
46. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
47. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Tsimberidou AM; Estey E; Whitman GJ; Dryden MJ; Ratnam S; Pierce S; Faderl S; Giles F; Kantarjian HM; Garcia-Manero G
Leuk Res; 2004 Sep; 28(9):991-4. PubMed ID: 15234578
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
49. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
50. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
[TBL] [Abstract][Full Text] [Related]
51. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
[TBL] [Abstract][Full Text] [Related]
52. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
Mandelli F; Latagliata R; Avvisati G; Fazi P; Rodeghiero F; Leoni F; Gobbi M; Nobile F; Gallo E; Fanin R; Amadori S; Vignetti M; Fioritoni G; Ferrara F; Peta A; Giustolisi R; Broccia G; Petti MC; Lo-Coco F;
Leukemia; 2003 Jun; 17(6):1085-90. PubMed ID: 12764372
[TBL] [Abstract][Full Text] [Related]
53. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
[TBL] [Abstract][Full Text] [Related]
55. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
56. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
57. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
[TBL] [Abstract][Full Text] [Related]
58. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
59. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma Y; Liu L; Jin J; Lou Y
PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
[TBL] [Abstract][Full Text] [Related]
60. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]